Volodymyr I. Kabachnyy

Volodymyr I. Kabachnyy

Auto-generated profile, based on publicly available information

Volodymyr I. Kabachnyy

National University of Pharmacy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Chemistry of Heterocyclic Compounds
Verified
Journal Article
Closed access
PDF file
OVOlena D. Vlasova
Olena D. Vlasova
KKKonstantin Krolenko
Konstantin Krolenko
MNMaxim A. Nechayev
Maxim A. Nechayev
PSPavlo E. Shynkarenko
Pavlo E. Shynkarenko
VKVolodymyr I. Kabachnyy
Volodymyr I. Kabachnyy
SVSergiy Vlasov
Sergiy Vlasov

1 July 1989 in Pharmaceutical Chemistry Journal
Verified
Journal Article
Closed access
PDF file
VCV. P. Chernykh
V. P. Chernykh
VKV. I. Kabachnyi
V. I. Kabachnyi
VSViktoriia Shapovalova
Viktoriia Shapovalova
LPL. A. Porokhnyak
L. A. Porokhnyak
OBO. V. Beletskaya
O. V. Beletskaya
VSV. N. Savchenko
V. N. Savchenko

30 September 2024 in Psychiatry, Neurology and Medical Psychology
Verified
Journal Article
Open access
PDF file
IKI.V. Kabachna
I.V. Kabachna
VKV.I. Kabachnyy
V.I. Kabachnyy
Background. The incidence of multiple sclerosis (MS) in humans continues to steadily increase each year worldwide. The problem of improving the quality of life of such patients as well as the development of new drugs for MS remains a very relevant problem today. Objective – the goal of our work was the systematization and analysis of modern data on the etiology, pathogenesis, and classification of symptoms of MS to facilitate diagnosis and search for the most effective methods of its treatment. Materials and Methods. We used during the detaliled analysis of modern literary sources helped us to collect and systematize data on the epidemiology of MS, its etiopathogenesis, classification, diagnosis and treatment, which allowed us to establish trends in the development of MS. Results. The prevalence of MS in the world continues to grow and today there are more than 2.5 million registered cases. The development of MS involves complex interactions between the immune system, genetic factors, and external influences (climate, viral component, bad habits, etc.). Despite the presence of many risk factors, MS remains a multifactorial disease, and the exact cause of its occurrence requires detailed diagnosis. But the following trend is clearly observed – the greater the totality of EF, the higher the chance of developing MS. The symptom complex of MS depends on the localization of lesions of the CNS and PNS nerves. Diagnostics includes many instrumental and laboratory research methods. Treatment of this pathology includes a combination of medicinal and non-medicinal methods, the main goal of which is aimed at reducing symptoms and slowing down the severity of their development, thereby increasing the quality of life of such patients. Conclusions. During the analysis of literary sources, it was established that MS is a heterogeneous, chronic, autoimmune, inflammatory, demyelinating disease of the central nervous system (CNS) with damage to the white matter of the brain (BM), spinal cord (CM) and optic nerves, which can lead to partial or complete disability depending on the location and degree of nerve damage, and detection of this problem in the early stages prevents aggravation and slows down the progression of the disease, and the search for new original methods of pharmacotherapy of this pathology remains an urgent problem today.

12 April 2021 in Ukrainian biopharmaceutical journal
Verified
Journal Article
Open access
PDF file
VKV.I. Kabachny
V.I. Kabachny
ОMО. Mamina
О. Mamina
NBN. Bondarenko
N. Bondarenko
OMO. Mozgova
O. Mozgova
Topicality. Сlemastine fumarate (tavegil)-1-methyl-2 [2-α-methyl-p-chlorobenzhydryloxy)-ethyl]-pyrrolidine fumarate is the first generation H1-histamine receptor blocker. Сlemastine fumarate selectively inhibits histamine H1 receptors and reduces capillary permeability. The drug has a pronounced anti-allergic and antipruritic effect. Clemastine prevents the development of vasodilation and the smooth muscle contraction induced by histamine. Сlemastine fumarate has an isignificant anticholinergic activity, causes sedation. The drug is used to treat pruritus in psoriasis, multiple sclerosis and optic neuritis. Clemastine is characterized by the following side effects: increased fatigue, drowsiness, sedation, weakness, lethargy, impaired coordination of movements; nausea, vomiting, decreased blood pressure, palpitations, hemolytic anemia, skin rash, anaphylactic shock. In case of an overdose, the drug has a neurotoxic effect, which manifests itself in impaired consciousness with the development of generalized anticholinergic convulsive syndrome. The urgent task for monitoring the treatment effectiveness of the population with сlemastine fumarate and diagnosis of drug intoxication is the choice of highly sensitive and selective research methods of its analysis in pharmaceuticals and biological matrices during the treatment. Aim. To develop an algorithm for directed analysis of clemastine in biological extracts from the blood using a unified method of the HPLC research. Materials and methods. The extraction of clemastine was performed with chloroform at Ph 9.0. The extracts were purified from impurities by a combination of TLC and extraction with hexane. The TLC purification and identification of clemastine were carried out under optimal conditions: the system of organic solvents – methanol – 25 % solution of ammonium hydroxide (100 : 1.5) and chromatographic plates – Sorbfil PTLC-AF-A, Rf сlemastine = 0.60 ± 0.03. To detect clemastine, the most sensitive location reagents were used –UV light (λ = 254 nm) and Dragendorff’s reagent modified by Mounier. The chromatographic analysis was performed on a “Milichrome A-02” microcolumn liquid chromatograph (EkoNova, Closed Joint-Stock Company, Russia) under standardized HPLC conditions: the reversed-phase variant using a metal column with a non-polar absorbent Prontosil 120-5C 18 AQ, 5 μm; the mobile phase in the linear gradient mode – from eluent А (5 % acetonitrile and 95 % buffer solution – 0.2 М solution of lithium perchlorate in 0.005 М solution of perchloric acid) to eluent B (100 % acetonitrile) for 40 min. Regeneration of the column was conducted for 2 min with the mixture of solvents; the flow rate of the mobile phase was 100 μl/min, the injection volume – 4 μl. The multichannel detection of the substance was performed using a two-beam multi-wave UV spectrophotometer at 8 wavelengths of 210, 220, 230, 240, 250, 260, 280, and 300 nm; the optimal value of the column temperature – 37-40 °С and the pump pressure – 2.8-3.2 MPa. Results and discussion. Isolation of clemastine from the blood was performed according to the method developed, including the extraction with chloroform at pH 9.0; the extraction purification of extracts with hexane from impurities; the TLC purification and identification of clemastine. Using the unified HPLC method clemastine was identified by retention parameters and spectral ratios. For the quantitative determination, a calibration graph or the straight line equation corresponding to this graph were used. The results obtained indicated the reliability and reproducibility of the method. It was found that the relative uncertainty of the average result in the analysis of clemastine in the blood was ε = ± 4.63 %, the relative standard deviation of the average result was RSDx = 1.67 %. Conclusions. Clemastine was extracted with chloroform at pH 9.0 from the blood. Purification of extracts from co-extractive compounds was performed by combining TLC and extraction with hexane. It has been found that when isolating сlemastine from the blood according to the methods developed it is possible to determine 36.05-39.55 % of the substance (ε = ± 4.63 %, RSDx = 1.67 %). The method of TLC purification and identification of сlemastine in biogenic extracts was tested under the optimal conditions: the system of organic solvents – methanol – 25 % solution of ammonium hydroxide (100 : 1.5), the use of reagents – UV light, Dragendorff’s reagent modified by Mounier, Rf сlemastine = 0.60 ± 0.03 (Sorbfil PTLC-AF-A). The unified HPLC method for identification and quantification of сlemastine was tested in biogenic extracts from the blood according to the algorithm of the directed analysis developed. It has been found that сlemastine can be identified by the retention time – 25.997-26.011 min; the retention volume – 2599.7-2601.1 μl; spectral ratios – 0.741; 0.536; 0.096; 0.023; 0.027; 0.005; 0.003. The сlemastine content was determined by the equation S = 0.15 · 10-3 С + 0.14 · 10-3; the correlation coefficient was equal to 0.9998. Chromatographic methods can be recommended for implementation in practice of the Bureau of Forensic Medical Examination, poison control centers, clinical laboratories regarding the study of medicinal substances in biological objects.

20 October 2021 in Journal of Organic and Pharmaceutical Chemistry
Verified
Journal Article
Open access
PDF file
OMOlena O. Mamina
Olena O. Mamina
VKVolodymyr I. Kabachny
Volodymyr I. Kabachny
NBNataliia Yu. Bondarenko
Nataliia Yu. Bondarenko
OLOlena V. Lozova
Olena V. Lozova
Aim. To develop the unified method of the HPLC analysis of loratadine, which can allow obtaining reliable and reproducible results of the studies of pharmaceuticals and biological matrices for monitoring the treatment effectiveness.Materials and methods. The HPLC analysis was performed on a “Milichrome A-02” microcolumn liquid chromatograph under the following conditions: a reversed-phase variant, 2 × 75 mm column filled with a non-polar sorbent Prontosil 120-5 C18 AQ, 5 μm; the mobile phase in the mode of a linear gradient – from eluent А (5 % of acetonitrile and 95 % of a buffer solution) to eluent B (100 % of acetonitrile) for 40 min. The flow rate of the mobile phase was 100 μL/min; the injection volume was 4 μL. The multichannel detection of the substance was carried out using an UV-detector at 210, 220, 230, 240, 250, 260, 280 and 300 nm; the optimal value of the column temperature was 37 – 40 °С, and the pump pressure was 2.8 – 3.2 MPa.Results and discussion. As a result of the studies performed, the retention parameters of loratadine and spectral relationships were determined using the unified HPLC method. This made it possible to include the results obtained in the database for the identification of antihistamines in the therapeutic monitoring of the treatment with an individual drug or in the complex treatment of allergic reactions. The development of the quantitative determination of loratadine by HPLC on model solutions using various concentrations of the drug was carried out. The content of loratadine was determined by the equation S = 1.14 × 10-3C – 0.50 × 10-4; the correlation coefficient was 0.9998. It was found that the relative standard deviation RSD did not exceed 0.93 % when analyzing loratadine in the model solutions by HPLC.Conclusions. The identification and the quantitative determination of loratadine by the unified HPLC method have been conducted. The method allows obtaining reliable and reproducible research results. The results of the studies can be recommended for implementation in the practice of forensic bureaus, toxicological centers, and clinical laboratories.

31 October 2025 in Psychiatry, Neurology and Medical Psychology
Verified
Journal Article
Closed access
IKI.V. Kabachna
I.V. Kabachna
AFA.S. Filova
A.S. Filova
VKV.I. Kabachnyy
V.I. Kabachnyy
Background. Alzheimerʼs disease (AD) is the leading cause of dementia, accounting for over 60% of cognitive disorders. According to WHO data, in 2024 more than 55 million people live with dementia, with around 10 million new patients added annually, a signifcant proportion of whom have AD. The number of patients is projected to double by 2050. Purpose – to summarize current data on the pathogenesis, diagnosis, and treatment of AD, with a focus on biomarkers, a staged approach, and new types of therapy targeting β-amyloid, tau protein, and efective preventive measures. Materials and Methods. During the study, recent research and international clinical guidelines, including U.S. recommendations on AD treatment, were analyzed and systematized. Results. It was established that AD develops 15–25 years before clinical manifestations and is accompanied by the accumulation of amyloid (Aβ) and phosphorylated tau protein (p-tau), which are identifed using Core 1 biomarkers (Aβ42/40, p-tau181, p-tau217) and positron emission neuroimaging. Treatment includes acetylcholinesterase inhibitors (donepezil, galantamine), memantine for moderate/severe forms, and modifed anti-Aβ antibodies (aducanumab, lecanemab), which require further evaluation of efcacy. Conclusions. AD has a long preclinical course and is currently considered incurable. Existing drugs and treatment methods are symptomatic and aimed at slowing the mechanisms of pathological protein formation and their elimination, which only delays neurodegeneration and the loss of essential life functions. In our opinion eliminating mitochondrial dysfunction, as the basis of pathological changes in neurons at all stages of AD progression, is an original and the most promising direction for the search and development of new drugs and therapeutic approaches.